Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zotiraciclib for Recurrent Malignant Gliomas With IDH1 or IDH2 Mutations
NCT05588141Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2023
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
A Phase 2 trial of zotiraciclib in Diffuse Glioma (DG), sponsored by National Cancer Institute. Started May 2023; status: recruiting.
02
Drugs
zotiraciclib
03
Conditions
Diffuse Glioma (DG)
Beyond the preview
Go deeper on NCT05588141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05588141.